Epithelial Cell Adhesion Molecule in Primary Sjögren’s Syndrome Patients: Characterization and Evaluation of a Potential Biomarker

Table 1

Demographic, clinical, and serological features of study participants.

	Non-SS controls	pSS patients at early stage	value	pSS patients at advanced stage	value	pSS patients included in study	value
Histopathologic grade	G0, 20 (100%)	G1-2, 16 (100%)	<0.001	G3-4, 31 (100%)	<0.001	G1-2, 16 (34.0%), G3-4, 31 (66.0%)	<0.001
Female sex	4 (20%)	14 (87.5%)	<0.001	29 (93.5%)	<0.001	43 (91.5%)	<0.001
Age at the inclusion (year)	44 (17, 58)	44 (19, 45)	ns	52 (25, 80)	ns	50 (19, 80)	ns
Disease duration (year)	<1 (<1, 20)	<1 (<1, 10)	ns	4 (<1, 30)	0.02	2 (<1, 30)	ns
Xerophthalmia	6 (30%)	7 (43.8%)	ns	16 (51.6%)	ns	23 (48.9%)	ns
Xerostomia	10 (50%)	10 (62.5%)	ns	28 (90.3%)	0.001	38 (80.9%)	0.01
Saprodontia	2 (10%)	8 (50%)	0.011	16 (51.6%)	0.002	24 (51.1%)	0.002
Anti-Ro/SSA	4 (20%)	10 (62.5)	0.016	17 (54.8%)	0.014	27 (57.4%)	0.005
Anti-La/SSB	6 (30%)	4 (25%)	ns	9 (29.0%)	ns	13 (27.7%)	ns
ANA	12 (60%)	12 (75%)	ns	29 (93.5%)	0.010	41 (87.2%)	0.029
RF (≥IU/mL)	7 (35%)	7 (43.8%)	ns	20 (64.5%)	0.039	27 (57.4%)	ns
ANA and RF	4 (20%)	5 (31.3%)	ns	20 (64.5%)	0.002	25 (53.2%)	0.012
Anti-Ro52	6 (30%)	9 (56.3%)	ns	18 (58.1%)	0.05	27 (57.4%)	0.04
IgG (mg/dL)	1515 (15, 3830)	1875 (796, 3100)	ns	1975 (154, 4400)	ns	1900 (154, 4400)	ns
ESR (mm/hr)	30 (4, 104)	48.5 (2, 120)	ns	40 (4, 140)	ns	45 (2, 140)	ns